Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk

A method for determining if cells in a sample express Pro108 comprising

• (a) contacting a sample of cells with a Pro108 antibody under conditions suitable for specific binding of the Pro108 antibody to Pro108 and
• (b) determining the level of binding of the antibody to cells in the sample, or the level of Pro108 antibody internalization by cells in said sample,
• wherein the Pro108 antibody is selected from:
• (i) an isolated antibody or antigen binding fragment specific for Pro108 produced by a hybridoma selected from the group consisting of ATCC Accession Number PTA-5885 and PTA-5886;
• or
• (ii) an isolated antibody or antigen binding fragment which competes for binding to the same epitope of Pro108 recognized by the antibody produced by a hybridoma selected from the group consisting of ATCC Accession Number PTA-5885 and PTA-5886;
• and
• wherein Pro108 antibody binding to cells in the sample or internalization of the Pro108 antibody by cells in the sample indicate cells in the sample express Pro108.

A method for monitoring a Pro108-expressing cancer in a subject in need thereof comprising,

• (a) measuring Pro108 levels over time in a sample from a subject with a Pro108 antibody under conditions suitable for specific binding of the Pro108 antibody to Pro108 in said sample, and
• (b) comparing Pro108 levels determined over time to a baseline or normal control,
• wherein the Pro108 antibody is selected from:
• (i) an isolated antibody or antigen binding fragment specific for Pro108 produced by a hybridoma selected from the group consisting of ATCC Accession Number PTA-5885 and PTA-5886;
• or
• (ii) an isolated antibody or antigen binding fragment which competes for binding to the same epitope of Pro108 recognized by the antibody produced by a hybridoma selected from the group consisting of ATCC Accession Number PTA-5885 and PTA-5886;
• and
• wherein an increase in Pro108 binding over time is indicative of progression of cancer and a decrease in Pro108 binding over time is indicative of regression of cancer.

A method for detecting Pro108 overexpression in a test cell sample, comprising:

• (a) combining a test cell sample with a Pro108 antibody under conditions suitable for specific binding of Pro108 to Pro108 expressed by cells in said test sample
• (b) determining the level of binding of the Pro108 antibody to the cells in the test sample, and
• (c) comparing the level of Pro108 antibody bound to the cells in step (b) to the level of Pro108 antibody binding to cells in a control cell sample,
• wherein the Pro108 antibody is selected from:
• (i) an isolated antibody or antigen binding fragment specific for Pro108 produced by a hybridoma selected from the group consisting of ATCC Accession Number PTA-5885 and PTA-5886;
• or
• (ii) an isolated antibody or antigen binding fragment which competes for binding to the same epitope of Pro108 recognized by the antibody produced by a hybridoma selected from the group consisting of ATCC Accession Number PTA-5885 and PTA-5886;
• and
• wherein an increase in the binding of the Pro108 antibody in the test cell sample as compared to the control is indicative of Pro108 overexpression by cells in the test cell sample.

A method for detecting Pro108 overexpression in a subject in need thereof comprising,

• (a) combining a sample of a subject with a Pro108 antibody under conditions suitable for specific binding of the Pro108 antibody to Pro108 in said sample
• (b) determining the level of Pro108 in the sample, and
• (c) comparing the level of Pro108 determined in step (b) to the level of Pro108 in a control,
• wherein the Pro108 antibody is selected from:
• (i) an isolated antibody or antigen binding fragment specific for Pro108 produced by a hybridoma selected from the group consisting of ATCC Accession Number PTA-5885 and PTA-5886;
• or
• (ii) an isolated antibody or antigen binding fragment which competes for binding to the same epitope of Pro108 recognized by the antibody produced by a hybridoma selected from the group consisting of ATCC Accession Number PTA-5885 and PTA-5886;
• and
• wherein an increase in the level of Pro108 in the sample from the subject as compared to the control is indicative of Pro108 overexpression in the subject.

A method for assessing risk of prostate cancer in a patient which comprises measuring levels of Pro108 and Prostate Specific Antigen (PSA) in a sample obtained from the patient to assess the risk of prostate cancer in the patient wherein Pro108 is measured with an antibody selected from:

• (i) an isolated antibody or antigen binding fragment specific for Pro108 produced by a hybridoma selected from the group consisting of ATCC Accession Number PTA-5885 and PTA-5886;
• or
• (ii) an isolated antibody or antigen binding fragment which competes for binding to the same epitope of Pro108 recognized by the antibody produced by a hybridoma selected from the group consisting of ATCC Accession Number PTA-5885 and PTA-5886, and
• wherein an elevated level of Pro108 as compared to a control is indicative of heightened risk of prostate cancer.

A method for assessing risk of ovarian or colon cancer in a patient which comprises measuring levels of Pro108 and Carcinoembryonic Antigen (CEA) in a sample obtained from the patient to assess the risk of ovarian or colon cancer in the patient wherein Pro108 is measured with an antibody selected from:

• (i) an isolated antibody or antigen binding fragment specific for Pro108 produced by a hybridoma selected from the group consisting of ATCC Accession Number PTA-5885 and PTA-5886;
• or
• (ii) an isolated antibody or antigen binding fragment which competes for binding to the same epitope of Pro108 recognized by the antibody produced by a hybridoma selected from the group consisting of ATCC Accession Number PTA-5885 and PTA-5886, and
• wherein an elevated level of Pro108 as compared to a control is indicative of heightened risk of ovarian or colon cancer.

A method for assessing risk of ovarian, lung or colon cancer in a patient which comprises measuring levels of Pro108 and CA19.9 in a sample obtained from the patient to assess the risk of ovarian, lung, or colon cancer in the patient wherein Pro108 is measured with an antibody selected from:

• (i) an isolated antibody or antigen binding fragment specific for Pro108 produced by a hybridoma selected from the group consisting of ATCC Accession Number PTA-5885 and PTA-5886;
• or
• (ii) an isolated antibody or antigen binding fragment which competes for binding to the same epitope of Pro108 recognized by the antibody produced by a hybridoma selected from the group consisting of ATCC Accession Number PTA-5885 and PTA-5886, and
• wherein an elevated level of Pro108 as compared to a control is indicative of heightened risk of ovarian, lung or colon cancer.

A method for assessing risk of ovarian cancer in a patient which comprises measuring levels of Pro108 and CA125 in a sample obtained from the patient to assess the risk of ovarian cancer in the patient wherein Pro108 is measured with an antibody selected from:

• (i) an isolated antibody or antigen binding fragment specific for Pro108 produced by a hybridoma selected from the group consisting of ATCC Accession Number PTA-5885 and PTA-5886;
• or
• (ii) an isolated antibody or antigen binding fragment which competes for binding to the same epitope of Pro108 recognized by the antibody produced by a hybridoma selected from the group consisting of ATCC Accession Number PTA-5885 and PTA-5886, and
• wherein an elevated level of Pro108 as compared to a control is indicative of heightened risk of ovarian cancer.